Rossari Biotech is a specialty chemicals converter with three core B2B segments — Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN) — plus an institutional and consumer cleaning business that is now close to breakeven. The business buys petrochemical and oleochemical inputs, including ethylene oxide (EO), and converts them into formulated surfactants, preservatives, textile auxiliaries, pharma excipients and feed additives. The economic case is not a commodity-cycle bet. It is an operating-leverage bet: the company has built ethoxylation and blending capacity, raised exports, and is trying to shift mix toward higher-margin pharma, oil and gas and specialty products. Q2 FY27 is the first clean evidence that the new assets can earn, but consolidated margins are still below the medium-term target.
At the reported level, Q2 FY27 revenue was ₹697.6 crore, up 19% YoY, EBITDA was ₹87 crore, up 21%, and PAT was ₹38.9 crore, up 5.5%. Gross margin was 31.6% and EBITDA margin 12.5%, up from 11.6% in Q1 FY27. The core B2B business, excluding institutional and consumer, earned a 14.1% EBITDA margin on ₹619.9 crore of revenue, up 21%. That is a respectable specialty-chemical margin, but it is below the 15–16% normalized band management has referenced and well below the 18% earned around the IPO. The gap is the opportunity and the risk.
The first mechanism is capacity utilisation. Rossari has 66,000 MTPA of installed ethoxylation capacity at Dahej. The new ethoxylation facility was at about 30% utilisation in Q2 FY27, with blended utilisation near 60%; management targets peak utilisation by end-FY28 and guides 3x capex value as peak sales for that capacity. The gating item is EO. India has a single domestic supplier, Reliance, whose expansion has slipped repeatedly. Q2 FY27 says the prior quarter had an EO constraint, hopes Q2 will not, and expects the supplier expansion in 2–3 quarters; in Q&A management guided higher allocation from Q1 FY28, with no confirmed quantity. This is the central inference in the thesis: if Reliance delivers incremental EO, the new continuous ethoxylation asset can fill, mix can improve, and operating leverage can lift margins. If it does not, the asset stays sub-scale and the 3x peak-sales guide is deferred.
The second mechanism is export mix. Exports were 31% of Q2 FY27 revenue and 27% of H1, and management targets at least 30% for FY27. Textile export revenue grew about 50% YoY in Q2, helped by the Thailand blending plant and new geographies across Southeast Asia, Africa and Latin America. Thailand is small — built for ₹10–15 crore, with ₹2–3 crore of Q1 FY27 revenue and a ₹50–75 crore peak revenue guide — but it is a market-access asset that reduces turnaround time and freight exposure. A higher export share is not automatically higher margin, because freight has roughly doubled or tripled and not all customers absorb it, but it broadens the demand base and supports the textile franchise while domestic textile demand is soft.
The third mechanism is product mix. HPPC is 77% of FY26 revenue, but the higher-margin opportunities are pharma excipients, oil and gas, aroma chemicals and biosurfactants. Pharma is the most visible. The Unitop plant has EXCiPACT registration, which allows pharma surfactant exports without customer audits, while customer stability studies and approvals still take 6 months to 2 years. Pharma exports were about ₹50 crore last year and management expects good growth this year. The old research carried a ₹70–75 crore FY27 target, but Q1 FY27 itself contained a conflicting ₹30–50 crore figure and Q2 did not reaffirm either number. The correct treatment is to see pharma as a real but slow-building, higher-margin revenue line, not a confirmed near-term number.
The fourth mechanism is portfolio cleanup. Institutional and B2C revenue was ₹77.7 crore in Q2 FY27, up 3%, with positive EBITDA of ₹0.2 crore versus a ₹3.7 crore loss in Q2 FY26. Management aims for H2 FY27 EBITDA positive and full-year at least breakeven, while retaining the plan to exit B2C at an appropriate time and value. The B2C business carried about ₹50 crore of debt on the Q1 FY27 call. A sale at a reasonable value would remove a drag and release capital, but no timeline or buyer has been disclosed. Until then, the benefit is the narrower loss, not a completed exit.
Capital allocation is more disciplined than in the build phase. Net debt fell to ₹221 crore in Q2 FY27 from ₹281 crore in March, gross borrowings were ₹361.8 crore, and working-capital days improved to 86 from 97 at FY26 end. Management says working-capital debt should be repaid by mid-next year, while long-term borrowings follow their own trajectory; the earlier 18-month all-debt target is therefore less clean. H2 FY27 capex is ₹50–70/75 crore across pharma, aroma, hydrogenation and biosurfactant projects, most closing by FY27 end, with no significant India capex next year. The KSA project has a Board-approved land lease but no cost, feedstock contract or commissioning date; it is an option, not yet a funded project.
Management delivery is mixed. Revenue guidance has been met or raised, capacity has been commissioned, and Q2 FY27 shows margin progress. But the FY26 margin promise was missed, the B2C positive-EBITDA promise was missed, the EO timeline has slipped in every call, and the debt-free target has been narrowed. The market should therefore apply a discount to the 15% medium-term margin target until it appears in reported numbers. The current evidence supports a credible operating-leverage story with a visible first step, not a completed turnaround.
The falsifiers are concrete. A further delay in Reliance EO, or an allocation too small to fill the new ethoxylation train, would keep utilisation near 30% and push peak sales beyond FY28. A sustained freight or phenol spike that cannot be passed through would keep core B2B margin below 14–15%. A failed or delayed B2C sale would leave the ₹50 crore debt and the drag in the portfolio. Slow pharma customer approvals would delay the highest-margin mix shift. A KSA commitment before the blueprint is complete could divert cash from debt reduction. Against these, the positive markers are Q2 revenue growth of 19%, 12.5% consolidated EBITDA margin, 14.1% core B2B margin, 31% export share, positive B2C EBITDA and net debt at ₹221 crore.
The thesis is therefore operating leverage with execution risk. The company does not need a new strategic story; it needs the installed assets, the export franchise and the B2C cleanup to convert into sustained margin. Q2 FY27 moved that case forward. It did not prove the 15% target.
companyname: Rossari Biotech Limited ticker: ROSSARI sector: Specialty Chemicals Rossari Biotech Limited is a Mumbai-headquartered specialty chemicals manufacturer with over 28 years of operating history. The company makes surfactants, ethoxylates, preservatives, textile processing chemicals, and animal nutrition products, selling them to FMCG companies, agrochemical formulators, textile mills, and poultry feed manufacturers across India and 80+ export markets. FY26 consolidated revenue was ₹23...
Read the full report →margin expansion, new product segment, geographic expansion
For FY27, management guides revenue growth in the mid-to-high teens and consolidated EBITDA margin around 12% plus/minus, with the EBITDA percentage improving next year. Exports should be at least 30% of FY27 revenue. H2 FY27 institutional/B2C should be EBITDA positive and the full year at least breakeven. H2 FY27 capex is ₹50–70/75 crore, most projects close by FY27 end, and no significant India capex is planned next year. New ethoxylation capacity is targeted for peak utilisation by end-FY28, with 3x capex value as peak sales; additional Reliance EO allocation is expected from Q1 FY28, quantity unconfirmed. KSA land lease is approved, but no cost or timeline is set.
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Rossari Biotech Limited and 4,900+ companies.
5-day free pass. No card required.